Yige Fu, Drishti Rathod, Ehab M. Abo-Ali, Vikas V. Dukhande, & Ketan Patel. (2019). EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma. MDPI AG.
Chicago Style (17th ed.) CitationYige Fu, Drishti Rathod, Ehab M. Abo-Ali, Vikas V. Dukhande, and Ketan Patel. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma. MDPI AG, 2019.
MLA (9th ed.) CitationYige Fu, et al. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma. MDPI AG, 2019.
Warning: These citations may not always be 100% accurate.